Great stats bro, in fact IMO on the conservative side. There is one vital observation that I feel is missing….. POOR Management.
There are 2 major ongoing concerns. Mast has some great workers and seems like they have fine people but from past testing’s what has been successful?
Unless management changes this is a simple $1.00-2.00 stock. I had an opportunity to speak to Mr. Culley personally in the spring. He is very likable and is making every effort at success but he just does not have the “skills.” After asking about failed tests in of 2011 he shared that there were opportunities to retest but felt that would not be beneficial. This was when company ANX. If you made an “F” on a test and the professor acknowledged what went wrong, and you could retest knowing you are guaranteed higher than “d” you refuse future tests? This was in July of 2011. I actually am one of the few longs and bought in Nov or December of 2011 after price dropped under a dollar. The other concern is compensation. Again no problem with any CEO making millions. They are under enormous stress and well deserve compensation. My issue was while company drops 60-70% of stock value, CEO doubles his own salary and bonuses. That is like a business asking employee do drop salary by 50% and yet the president of that business doubles his. How would you like that working at that business?
There is a simple remedy to the problem, but I know they will never do it. Do it, stock would double within a month on no news whatsoever. Even today PR should have raised this 10-15% but past failures equal fearful investors.
Move Mr. Culley out as CEO and get a qualified individual with success and proven track record in the bio field. Move Mr. Culley to exclusively financials. You have to applaud his tenacity and ability to bring on institutional buyers. Hats off to him in that area, plus even though I hated the offering, it did bring in money. Financials are setting good with no borrowing until 2017 at earliest. That took some work, but past inability to have any successful bio tests disqualify him from being head CEO. In fact buyers are both fearful and will not jump in based on this fact alone. Very few longs here based on fear of another failed test therefore this becomes a “flip” or “short” stock.
I bought in just under a dollar. Doubled twice in forties and again in upper 30’s couple months back. Setting at .5102 so doing just fine. Still hate it for other that had no outlet planning. Hope I do not sound negative, I am not. Just know this stock could be easily much higher with better management. Good luck either way ….
AI
